99 related articles for article (PubMed ID: 6511307)
21. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.
al-Jafari AA; Kamal MA; Greig NH; Alhomida AS; Perry ER
Biochem Biophys Res Commun; 1998 Jul; 248(1):180-5. PubMed ID: 9675107
[TBL] [Abstract][Full Text] [Related]
22. Spontaneously reactivation of acetylcholinesterase inhibited by diisopropylfluorophosphate.
Lanks KW; Seleznick MJ
Biochim Biophys Acta; 1981 Jul; 660(1):91-5. PubMed ID: 7272315
[TBL] [Abstract][Full Text] [Related]
23. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase.
Perola E; Cellai L; Lamba D; Filocamo L; Brufani M
Biochim Biophys Acta; 1997 Nov; 1343(1):41-50. PubMed ID: 9428657
[TBL] [Abstract][Full Text] [Related]
24. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge.
Eckert S; Eyer P; Worek F
Toxicology; 2007 Apr; 233(1-3):180-6. PubMed ID: 17097792
[TBL] [Abstract][Full Text] [Related]
25. Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands.
Szegletes T; Mallender WD; Rosenberry TL
Biochemistry; 1998 Mar; 37(12):4206-16. PubMed ID: 9521743
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.
Pietsch M; Gütschow M
J Med Chem; 2005 Dec; 48(26):8270-88. PubMed ID: 16366609
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase.
Boyle NA; Talesa V; Giovannini E; Rosi G; Norton SJ
J Med Chem; 1997 Sep; 40(19):3009-13. PubMed ID: 9301662
[TBL] [Abstract][Full Text] [Related]
28. Interaction and inhibition of acetylcholinesterase from Electrophorus electricus by nitrosamines.
Shuttleworth B; de Villiers DL; Whiteley CG
Arch Biochem Biophys; 1990 Jun; 279(2):338-44. PubMed ID: 2350180
[TBL] [Abstract][Full Text] [Related]
29. Histochemical demonstration of acetylcholinesterase activity in human Meibomian glands.
Perra MT; Serra A; Sirigu P; Turno F
Eur J Histochem; 1996; 40(1):39-44. PubMed ID: 8741098
[TBL] [Abstract][Full Text] [Related]
30. Identical kinetics of human erythrocyte and muscle acetylcholinesterase with respect to carbamate pre-treatment, residual activity upon soman challenge and spontaneous reactivation after withdrawal of the inhibitors.
Herkert NM; Eckert S; Eyer P; Bumm R; Weber G; Thiermann H; Worek F
Toxicology; 2008 Apr; 246(2-3):188-92. PubMed ID: 18304715
[TBL] [Abstract][Full Text] [Related]
31. Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor.
Bartolini M; Cavrini V; Andrisano V
J Chromatogr A; 2007 Mar; 1144(1):102-10. PubMed ID: 17134713
[TBL] [Abstract][Full Text] [Related]
32. 3-Fluoro-2,4-dioxa-3-phosphadecalins as inhibitors of acetylcholinesterase. A reappraisal of kinetic mechanisms and diagnostic methods.
Baici A; Schenker P; Wächter M; Rüedi P
Chem Biodivers; 2009 Mar; 6(3):261-82. PubMed ID: 19319863
[TBL] [Abstract][Full Text] [Related]
33. Physostigmine analogs anticholinesterases: effects of the lengthening of the N-carbamic chain on the inhibition kinetics.
Marta M; Gatta F; Pomponi M
Biochim Biophys Acta; 1992 Apr; 1120(3):262-6. PubMed ID: 1576152
[TBL] [Abstract][Full Text] [Related]
34. Kinetic evidence for different mechanisms of acetylcholinesterase inhibition by (1R)- and (1S)-stereoisomers of isomalathion.
Jianmongkol S; Marable BR; Berkman CE; Talley TT; Thompson CM; Richardson RJ
Toxicol Appl Pharmacol; 1999 Feb; 155(1):43-53. PubMed ID: 10036217
[TBL] [Abstract][Full Text] [Related]
35. Internal flexibility of inhibitors bound to Electrophorus electricus acetylcholinesterase: proton nuclear magnetic resonance spectroscopy.
Marshall AG; Carruthers JM
Mol Pharmacol; 1981 Jul; 20(1):89-97. PubMed ID: 7290088
[No Abstract] [Full Text] [Related]
36. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
37. Batchwise covalent immobilization of human acetylcholinesterase: kinetic and inhibition spectrophotometric studies.
Bartolini M; Cavrini V; Andrisano V
Anal Biochem; 2005 Jul; 342(1):163-6. PubMed ID: 15958194
[No Abstract] [Full Text] [Related]
38. Modification of acetylcholinesterase during adaptation to chronic, subacute paraoxon application in rat.
Milatovic D; Dettbarn WD
Toxicol Appl Pharmacol; 1996 Jan; 136(1):20-8. PubMed ID: 8560475
[TBL] [Abstract][Full Text] [Related]
39. [Biochemical characteristics of aminostigmine--a new anticholinesterase agent].
Prozorovskiĭ VB; Rozengart VI; Ardab'eva TV; Kugusheva LI; Suslova IM
Biokhimiia; 1996 Apr; 61(4):690-6. PubMed ID: 8724787
[TBL] [Abstract][Full Text] [Related]
40. Effect of physostigmine on cholinesterase activity in different parts of rat brain.
Osman MY; Abdel Tawab SM; Sharaf IA
Arzneimittelforschung; 1995 Jun; 45(6):663-5. PubMed ID: 7646566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
